Investor Conviction Tested Amidst Steep Declines

In an Indian market often swayed by momentum, the steadfastness of seasoned investors like Radhakishan Damani and the estate of the late Rakesh Jhunjhunwala offers a stark contrast to ephemeral retail sentiment. Both investors are maintaining significant positions in Concord Biotech and BF Utilities, companies that have experienced precipitous stock price corrections exceeding 55% and 80% from their all-time highs, respectively. This divergence between market pricing and institutional holding underscores a fundamental philosophy prioritizing long-term value and operational strength over short-term volatility.

Concord Biotech: Operational Strength Amidst Margin Headwinds

Concord Biotech, a biopharmaceutical firm specializing in fermentation-based APIs for immunosuppressants and oncology, has seen its market capitalization hover around ₹12,800 crore as of late February 2026 [8, 35]. The company's stock, after reaching a peak of approximately ₹2,664 in September 2024, has corrected by over 55% to trade near ₹1,100 [10, 15, 33]. This decline follows a reported contraction in sales and EBITDA for the first three quarters of FY26 compared to the previous year [News1]. High initial costs associated with its new Valthera injectable facility and the U.S. subsidiary, Stellon Biotech, have also impacted profitability, creating a drag on margins [News1].

Despite these headwinds, Concord Biotech presents compelling operational metrics. Its Return on Capital Employed (ROCE) stands at a robust 28-30%, significantly outperforming the pharmaceutical industry median of around 15% [News1, 8]. The company is also virtually debt-free, a key differentiator that mitigates interest burdens and enhances financial flexibility [News1]. Analysts maintain a generally "Buy" or "Outperform" rating, with a 12-month average price target around ₹1,427, though some recent target revisions have been downwards [5, 12, 17, 25]. The stock's current Price-to-Earnings (P/E) ratio, hovering between 36x and 40x [8, 10, 35], is above the Indian pharmaceutical industry average P/E of approximately 26.4x, suggesting investors are paying a premium for its strong capital efficiency and market position [41]. Recent quarterly results indicated that EPS and revenues missed analyst expectations [25].

BF Utilities: Navigating Leverage and Liabilities

BF Utilities Ltd., engaged in wind power generation and infrastructure, has experienced an even sharper correction, with its share price falling over 80% from its peak of ₹2,628 to around ₹490-₹500 as of late February 2026 [14, 20, 21, 26]. While sales dipped year-on-year in the first nine months of FY26, EBITDA and net profits showed modest year-on-year increases [News1]. However, the market is aggressively discounting significant risks, notably a contingent liability of approximately ₹500 crore stemming from an arbitration award against its subsidiary, NECE [News1]. The company also carries a substantial debt-to-equity ratio of 4.7x, creating a considerable interest burden and limiting financial maneuverability [News1].

Despite these concerning factors, BF Utilities boasts a strong historical ROCE, with a 10-year average of 18%, far exceeding the industry median of 7% [News1]. The current stock trades at a P/E ratio in the range of 5x to 15x, significantly below the industry median of 21x and its own historical averages [9, 20, 26, 29, 42]. This discount signals market skepticism regarding its balance sheet and contingent liabilities. The company recently settled with SEBI for alleged listing norm violations, involving over ₹3.6 crore in February 2026 [News1]. While the core wind power sector benefits from India's push towards renewable energy, with significant capacity additions and investment targets [39, 40, 44], BF Utilities' specific financial structure presents a formidable challenge.

The Price of Conviction: Strategy Over Sentiment

Radhakishan Damani's investment philosophy is rooted in value investing, a long-term vision, and rigorous risk management, often favoring fundamentally sound, less cyclical businesses with strong capital efficiency [1, 6, 11, 18, 19]. The estate of Rakesh Jhunjhunwala, by holding a substantial stake in Concord Biotech, demonstrates a similar faith in underlying value rather than short-term market movements. These veteran investors appear to prioritize attributes like strong return on capital, manageable debt (or lack thereof for Concord), and potential for future operational leverage over immediate stock price performance. They are seemingly betting on the eventual normalization of margins at Concord Biotech and the successful resolution or management of liabilities at BF Utilities, viewing the current steep discounts as opportunities rather than reasons for exit.

The Forensic Bear Case

Concord Biotech's valuation, while supported by high ROCE, appears stretched at 36-40x P/E compared to its pharmaceutical peers averaging 26-33x, making it vulnerable to any earnings miss [41]. The reported miss on Q3 FY26 earnings further amplifies this concern [25]. For BF Utilities, the situation is more precarious. The 4.7x debt-to-equity ratio is a significant red flag, creating substantial interest costs and financial fragility [News1]. The contingent liability of ₹500 crore and the recent SEBI settlement highlight ongoing governance and legal risks that the market is pricing in heavily, pushing its P/B ratio to over 9x [News1]. Despite historical ROCE strength, the poor quality and management scores from some analyses [48] and the lack of clear analyst coverage suggest considerable investor apprehension. The company's poor sales growth over the last five years (-0.71% CAGR) and low ROE over the last three years (7.32%) further darken the outlook [20].

Future Outlook

Analysts project revenue growth for Concord Biotech in the 17-24% range annually over the next three years, with EPS growth anticipated at 23.7% [25]. The consensus price target suggests a potential upside of up to 30% from current levels [5]. The Indian pharmaceutical sector itself is poised for steady growth, driven by domestic demand and increasing global relevance in generics and specialty products [2, 3, 4]. Conversely, specific forward-looking analyst estimates for BF Utilities are not readily available. The company operates within the power generation sector, a critical area for India's growth, but its specific financial structure and liabilities suggest a more speculative outlook. Investors must weigh the formidable risks against the potential for a turnaround, a decision mirroring the conviction displayed by Damani and the Jhunjhunwala estate.